IRIS
VOSO, MARIA TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 73.858
AS - Asia 8.860
EU - Europa 6.424
SA - Sud America 1.493
AF - Africa 145
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 26
Totale 90.837
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 73.612
SG - Singapore 3.994
IT - Italia 1.583
CN - Cina 1.571
BR - Brasile 1.243
RU - Federazione Russa 1.091
HK - Hong Kong 991
IE - Irlanda 771
VN - Vietnam 693
UA - Ucraina 682
DE - Germania 638
KR - Corea 502
FR - Francia 431
GB - Regno Unito 364
BD - Bangladesh 320
FI - Finlandia 290
JP - Giappone 250
IN - India 144
CA - Canada 132
NL - Olanda 129
PL - Polonia 98
SE - Svezia 96
AR - Argentina 88
AT - Austria 73
ID - Indonesia 70
MX - Messico 60
ES - Italia 54
ZA - Sudafrica 48
CO - Colombia 39
IQ - Iraq 38
TR - Turchia 33
AU - Australia 30
EC - Ecuador 30
PK - Pakistan 24
VE - Venezuela 24
PY - Paraguay 23
UZ - Uzbekistan 23
BE - Belgio 22
IR - Iran 22
PH - Filippine 22
EG - Egitto 21
MA - Marocco 21
EU - Europa 19
KZ - Kazakistan 17
LT - Lituania 17
CL - Cile 16
SA - Arabia Saudita 15
JO - Giordania 14
MY - Malesia 14
TH - Thailandia 14
KE - Kenya 13
DZ - Algeria 12
PE - Perù 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
CH - Svizzera 11
JM - Giamaica 11
NP - Nepal 11
AZ - Azerbaigian 9
CZ - Repubblica Ceca 9
TN - Tunisia 9
CR - Costa Rica 8
DO - Repubblica Dominicana 8
RO - Romania 8
TW - Taiwan 8
AL - Albania 7
IL - Israele 7
GT - Guatemala 6
HR - Croazia 6
KG - Kirghizistan 6
BG - Bulgaria 5
BO - Bolivia 5
PS - Palestinian Territory 5
SN - Senegal 5
TT - Trinidad e Tobago 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BN - Brunei Darussalam 4
GE - Georgia 4
GR - Grecia 4
HU - Ungheria 4
MD - Moldavia 4
MK - Macedonia 4
RS - Serbia 4
BB - Barbados 3
LU - Lussemburgo 3
NG - Nigeria 3
OM - Oman 3
PT - Portogallo 3
QA - Qatar 3
SY - Repubblica araba siriana 3
A1 - Anonimo 2
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BY - Bielorussia 2
BZ - Belize 2
CY - Cipro 2
GD - Grenada 2
HN - Honduras 2
Totale 90.798
Salva come PNG Salva come JPEG
Città #
Houston 22.126
Woodbridge 18.291
Wilmington 16.090
Fairfield 2.305
Singapore 2.195
Ashburn 1.496
Ann Arbor 1.486
San Jose 1.042
Hong Kong 978
Seattle 911
Cambridge 834
Chandler 819
Dublin 710
Jacksonville 592
Dearborn 574
Beijing 569
Medford 527
Rome 470
New York 382
Santa Clara 372
The Dalles 345
Dallas 329
Council Bluffs 294
Lawrence 253
Los Angeles 250
Ho Chi Minh City 237
Lauterbourg 228
Tokyo 221
Moscow 176
Buffalo 147
Hanoi 143
Milan 138
Hangzhou 132
San Diego 120
São Paulo 110
Menlo Park 102
Helsinki 91
London 91
Chicago 70
Nuremberg 70
North Bergen 67
Orem 67
Redondo Beach 59
Boardman 58
Creede 52
Munich 52
Center 51
Seoul 44
Jakarta 43
Warsaw 42
Atlanta 41
Norwalk 41
Engelhard 40
Toronto 40
Frankfurt am Main 39
Kraków 39
Shanghai 39
Denver 36
Brooklyn 35
Da Nang 34
Rio de Janeiro 34
Chennai 33
Zhengzhou 33
Guangzhou 32
Montreal 32
Nanjing 32
Vienna 32
Florence 31
Hefei 31
Monte Vista 31
Phoenix 30
Naples 29
Mountain View 28
Bologna 27
Stockholm 27
Verona 27
Hackensack 26
Belo Horizonte 25
Haiphong 25
Baghdad 24
Redwood City 24
San Francisco 24
Amsterdam 23
Brasília 23
Lappeenranta 23
Johannesburg 22
Detroit 21
Curitiba 20
Columbus 19
Guarulhos 19
Brussels 18
Dhaka 18
Kunming 18
Pune 18
Bari 17
Mexico City 17
Porto Alegre 17
Washington 17
Manchester 16
Mumbai 16
Totale 78.214
Salva come PNG Salva come JPEG
Nome #
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after bupropion treatment for smoking cessation 2.381
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias 1.670
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS 1.637
Identification of a novel subpopulation of human cord blood CD34-CD133-CD7-CD45+lineage- cells capable of lymphoid/NK cell differentiation after in vitro exposure to IL-15 1.262
Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis 1.186
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 522
Therapy-related leukemia and myelodysplasia: susceptibility and incidence 511
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): Phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 506
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 501
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 477
Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes 469
Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study 468
A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry 466
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 466
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 462
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 460
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia 460
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 458
Clonal evolution in therapy-related neoplasms 457
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 454
Two promoters direct expression of the murine Spi-B gene, an Ets family transcription factor 454
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy 449
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 447
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 446
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 445
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin 444
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression 443
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 441
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 439
Panobinostat for the treatment of acute myelogenous leukemia 438
Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia 438
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer 436
New treatments for myelodysplastic syndromes 434
Therapy related leukemias: susceptibility, prevention and treatment 432
The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery 432
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 431
Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content 429
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 429
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 428
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 427
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System 427
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms 426
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 425
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 423
Small lymphocytic lymphoma in a patient with Fabry disease 423
Prevalence of the 677C to T mutation in the methylenetetrahydrofolate reductase gene in Italian patients with venous thrombotic disease 423
Why methylation is not a marker predictive of response to hypomethylating agents 422
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 421
Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms 420
Prevalence of obesity in young adults with acute lymphoblastic leukemia 419
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 418
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 418
Microchimerism in bone marrow-derived CD34(+) cells of patients after liver transplantation 418
Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects 417
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 416
In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study 415
Hepato-splenic mycotic abscesses in patients with acute leukemia 415
Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far? 414
Epigenetic changes in therapy-related MDS/AML 414
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 414
Mobilization and selection of CD34+ cells 411
Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer 410
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 410
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma 409
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 409
Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia 407
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 407
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes 406
Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients 405
Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia 405
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 405
Acute myeloid leukemia in elderly patients aged over 75 years: experience of a single centre 405
Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia 405
Incidence and susceptibility to therapy-related myeloid neoplasms 404
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 404
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 403
RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression 402
High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment 401
An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome 401
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia 401
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 400
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 400
Deferasirox chelation therapy in patients with transfusion-dependent MDS: A 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 399
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications 399
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial 399
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 398
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha 398
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study 398
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma 397
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 397
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 397
Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome 397
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial 396
Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B 395
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 394
The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia 393
Treatment of low-blast count AML using hypomethylating agents 392
Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias 391
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 391
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy 390
Totale 48.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 224.602
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 224.602
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021107 0 0 0 0 0 0 0 0 0 0 0 107
2021/20222.487 118 293 127 61 78 198 129 148 178 143 268 746
2022/20232.760 339 173 135 270 180 696 484 119 205 20 77 62
2023/20241.297 126 37 149 56 124 346 67 33 51 40 30 238
2024/20256.762 179 1.438 783 446 133 355 681 337 799 568 568 475
2025/202611.739 916 611 1.522 879 966 366 1.439 1.353 1.359 1.041 785 502
Totale 92.286